Harmonic Pharma has been founded in 2009 with a core technology dedicated to drug repurposing. The company has developed a platform to investigate the mechanism of action of any type of chemicals over the last years.
Complementary AI-based solutions have been developed through the dual program entitled Chemical Range to provide public and private organizations with a more comprehensive toxicity profiling.
December 2017, Seqens group announced his support to Harmonic Pharma through a capital increase. According to Pierre Luzeau, President of Seqens : “The access to Harmonic Pharma’s technology broadens Seqens’ services.